Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Thiogenesis Therapeutics Corp. announced its CEO will present at the 3rd Annual Leigh Syndrome Symposium, discussing TTI-0102, a potential treatment for Leigh syndrome and MELAS. The compound aims to combat mitochondrial oxidative stress by increasing glutathione levels, with Phase 2 clinical trials anticipated soon.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.